glycine/necrosis

BACKGROUND OF THE INVENTION The present invention relates to N-(aroyl)glycine hydroxamic acid derivatives and related compounds that are selective inhibitors of phosphodiesterase (PDE) type IV or of the production of tumor necrosis factor (TNF) and as such are useful in the treatment of asthma,

BACKGROUND OF THE INVENTION The present invention relates to N-(aroyl)glycine hydroxamic acid derivatives and related compounds that are selective inhibitors of phosphodiesterase (PDE) type IV or of the production of tumor necrosis factor (TNF) and as such are useful in the treatment of asthma,

FIELD OF INVENTION The invention provides stable pharmaceutical compositions comprising tumor necrosis factor receptor Fc fusion protein (TNFR:Fc). The invention also provides methods of manufacturing the composition, method of administration and kits containing the same. BACKGROUND OF

CROSS REFERENCE TO RELATED APPLICATIONS This Application claims priority of Taiwan Patent Application No. 099135701, filed on Oct. 20, 2010, the entirety of which is incorporated by reference herein. INCORPORATION BY REFERENCE OF SEQUENCE LISTING A sequence listing submitted as a text file via

BACKGROUND OF THE INVENTION The present invention relates to the use of specific amino acids in the preparation of a medicament or nutritional formulation which may be therapeutically administered to patients suffering from a wide variety of diseases and morbid conditions. It has now surprisingly

The present invention relates to a cyclic protein free from cysteines which can be used as a medicament, e.g., for activating epithelial ion channels, for improving the lung function as well as for treating oedemas such as pulmonary oedemas. The fluid transport through cell layers and tissue is